These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27815117)

  • 21. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
    Koryakova AG; Ivanenkov YA; Ryzhova EA; Bulanova EA; Karapetian RN; Mikitas OV; Katrukha EA; Kazey VI; Okun I; Kravchenko DV; Lavrovsky YV; Korzinov OM; Ivachtchenko AV
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3661-6. PubMed ID: 18502121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and docking studies of N-(5-(alkylthio)-1,3,4-oxadiazol-2-yl)methyl)benzamide analogues as potential alkaline phosphatase inhibitors.
    Iqbal Z; Iqbal A; Ashraf Z; Latif M; Hassan M; Nadeem H
    Drug Dev Res; 2019 Aug; 80(5):646-654. PubMed ID: 31032540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 27. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
    Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
    Saha D; Ryan KR; Lakkaniga NR; Smith EL; Frett B
    ChemMedChem; 2021 May; 16(10):1605-1608. PubMed ID: 33559353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
    Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
    J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
    Zhang S; Luo Y; He LQ; Liu ZJ; Jiang AQ; Yang YH; Zhu HL
    Bioorg Med Chem; 2013 Jul; 21(13):3723-9. PubMed ID: 23673215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current review of small molecule Ret kinase inhibitors.
    Zuercher WJ; Turunen BJ; Lackey KE
    Mini Rev Med Chem; 2010 Feb; 10(2):138-46. PubMed ID: 20105131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.
    Smith A; Ni ZJ; Poon D; Huang Z; Chen Z; Zhang Q; Tandeske L; Merritt H; Shoemaker K; Chan J; Kaufman S; Huh K; Murray J; Appleton BA; Cowan-Jacob SW; Scheufler C; Kanazawa T; Jansen JM; Stuart D; Shafer CM
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5221-5224. PubMed ID: 29107542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
    Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology.
    Moccia M; Frett B; Zhang L; Lakkaniga NR; Briggs DC; Chauhan R; Brescia A; Federico G; Yan W; Santoro M; McDonald NQ; Li HY; Carlomagno F
    J Med Chem; 2020 May; 63(9):4506-4516. PubMed ID: 32298114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere.
    Shao T; Wang J; Chen JG; Wang XM; Li H; Li YP; Li Y; Yang GD; Mei QB; Zhang SQ
    Eur J Med Chem; 2014 Mar; 75():96-105. PubMed ID: 24530495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors.
    Panchal II; Rajput R; Patel AD
    Curr Drug Discov Technol; 2020; 17(1):57-67. PubMed ID: 30398117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
    Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.